Sorry, you need to enable JavaScript to visit this website.

Sector Overview

India's biotechnology sector is rapidly emerging as a critical driver of economic and technological growth, holding approximately 4% of the global biotech market with notable strengths in vaccines, bio-pharmaceuticals, and agricultural biotechnology. The sector, divided into bio-pharma, bio-services, bio-agri, bio-industrial, and bio-informatics, is led by bio-pharma, with India supplying around 60% of the global demand for DPT, BCG, and measles vaccines.

Strategic government initiatives such as the National Biotechnology Development Strategy (NBDS) 2021-2025 support this growth by fostering a conducive environment for research, investment, and innovation. The COVID-19 pandemic highlighted India's biotech capabilities in vaccine development and manufacturing, emphasizing the sector's crucial role in public health. Biotechnology also addresses significant challenges in healthcare, agriculture, and environmental sustainability, with innovations like genetically modified crops, biopesticides, and biofertilizers enhancing food security and sustainable farming practices.

A strong network of research institutions, universities, and industry players, alongside public-private collaborations, drives the sector's success by translating scientific discoveries into commercial products. The establishment of biotech parks and incubators further supports startups with necessary infrastructure. 

Biotechnology is pivotal to India's future growth, with strategic government support and a thriving research ecosystem positioning the country to harness the sector's full potential and offer innovative solutions to global challenges, improving quality of life worldwide.

37%

Industrial R&D expenditure is in Biotechnology

9000+

Patents filed in the field of biotech (2022)

Why Invest in Biotechnology

  • Strategic Location for Integration of Global Supply Chain

    India’s proximity to emerging markets in Asia, Africa, and the Middle East positions it as a hub for cost-effective biotech exports and services.

  • Growing Biologics and Biosimilars Market

    India is rapidly becoming a global hub for biologics and biosimilars, leveraging expertise in producing affordable and high-quality therapies for regulated markets. 

  • Emphasis on Biomanufacturing

    India offers strong opportunities for public-private partnerships, backed by institutions like DBT-BRIC institutes for fostering collaborative R&D for development of cutting-edge biotech solutions.

  • Robust Clinical Trial Infrastructure

    A vast genetic diversity, cost-efficient clinical trials, and adherence to global regulatory standards make India a preferred destination for biotech testing and development.

Major Investors

Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image
Video Thumbnail Image

Incentives & Schemes

Policy Archive

img

BioE3 Policy, 2024

The ‘goal’ of the Policy is to fast-track innovation-to-technology in a sustainable manner by weaving together fragmented activities under the umbrella of biomanufacturing and to incentivize concrete options to build a sustainable future.